Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Todd J Janus

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2003
Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancerBernard A Zonnenberg, Gerard Groenewegen, Todd J Janus, et al.
Neuro-Oncology|April 4, 2003
A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant gliomaMichael D Prados, S Clifford Schold, Howard A Fine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblastsKarim Fizazi, Jun Yang, Sara Peleg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2002
Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokineticsMichael A Carducci, Joel B Nelson, M Kathy Bowling, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2003
Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancerBernard A Zonnenberg, Gerard Groenewegen, Todd J Janus, et al.
Neuro-Oncology|April 4, 2003
A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant gliomaMichael D Prados, S Clifford Schold, Howard A Fine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblastsKarim Fizazi, Jun Yang, Sara Peleg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2002
Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokineticsMichael A Carducci, Joel B Nelson, M Kathy Bowling, et al.
Pageof 2